|
Parkinsonian Disorders
|
0.700 |
Biomarker
|
group |
BEFREE |
To overcome this problem, we developed a non-invasive intranasal delivery system, chitosan coated niosomes with entrapped pentamidine (inPentasomes), in the attempt to provide a novel pharmacological approach to ameliorate parkinsonism induced by subchronic MPTP administration in C57BL-6 J mice. inPentasomes, prepared by evaporation method was administered daily by intranasal route in subchronic MPTP-intoxicated rodents and resulted in a dose-dependent manner (0.001-0.004 mg/kg) capable for a significant Tyrosine Hydroxylase (TH) positive neuronal density rescue in both striatum and substantia nigra of parkinsonian mice.
|
30529726 |
2019 |
|
Parkinsonian Disorders
|
0.700 |
Biomarker
|
group |
BEFREE |
Here, we investigated sex differences in motor deficits and tyrosine hydroxylase (TH) immunoreactivity induced by a progressive model of parkinsonism.
|
30690108 |
2019 |
|
Parkinsonian Disorders
|
0.700 |
AlteredExpression
|
group |
BEFREE |
Since TH protein has been shown to be involved in the dopamine-producing pathway in previous studies, our results indicate the possibility that manganese-mediated reduction of TH expression and phosphorylation via decreased expression of c-RET protein in neural cells is involved in parkinsonism induced by manganese.
|
28730349 |
2017 |
|
Parkinsonian Disorders
|
0.700 |
Biomarker
|
group |
BEFREE |
In an in vivo MPTP-induced animal model of Parkinson's disease, oral administration of compound 5b showed neuroprotection of nigrostriatal dopaminergic neurons as revealed by tyrosine hydroxylase staining and prevention of MPTP-induced parkinsonism as revealed by motor behavioral assay of vertical grid test.
|
28332824 |
2017 |
|
Parkinsonian Disorders
|
0.700 |
Biomarker
|
group |
BEFREE |
The provocation test was developed by a systemic administration of α-methyl-p-tyrosine (αMpT), a reversible inhibitor of tyrosine hydroxylase to MPTP-treated mice at the presymptomatic stage of parkinsonism.
|
27194433 |
2017 |
|
Parkinsonian Disorders
|
0.700 |
GeneticVariation
|
group |
BEFREE |
The mutation p.Arg233His was predicted to link to the second type of TH deficiency (dopa-responsive infantile parkinsonism with delayed motor development).
|
28087438 |
2017 |
|
Parkinsonian Disorders
|
0.700 |
AlteredExpression
|
group |
BEFREE |
BAs taken by rats with rotenone-induced parkinsonism showed enhanced general motor performance, reduced inflammatory markers, and increased striatal dopamine level and nigral tyrosine hydroxylase immunostaining.
|
28249117 |
2017 |
|
Parkinsonian Disorders
|
0.700 |
AlteredExpression
|
group |
BEFREE |
In the combined forms, dystonia is accompanied by parkinsonism (GCH1/DYT5a; TH/DYT5b; ATP1A3/DYT12; TAF1/DYT3) or myoclonus (SGCE/DYT11).
|
24262166 |
2014 |
|
Parkinsonian Disorders
|
0.700 |
AlteredExpression
|
group |
BEFREE |
For example, α-synuclein represses TH not only by inhibiting phosphorylation at Ser40 of TH, but also by stimulating protein phosphatase 2A activity, which decreases dopamine synthesis and leads to parkinsonism.
|
22483316 |
2012 |
|
Parkinsonian Disorders
|
0.700 |
GeneticVariation
|
group |
BEFREE |
Consistent with the essential role of TH in dopamine homeostasis, missense mutations in both alleles of TH have been associated with severe Parkinsonism-related phenotypes including infantile Parkinsonism.
|
22583432 |
2012 |
|
Parkinsonian Disorders
|
0.700 |
GeneticVariation
|
group |
BEFREE |
Patients with the dystonia plus syndrome DYT5 display levodopa-responsive dystonia sometimes associated with tremor or parkinsonism (DYT5a, mutations in GCH1); a more severe phenotype with psychomotor involvement can be seen in recessive forms (DYT5b with TH mutations, SPR-deficiency syndrome).
|
22166420 |
2012 |
|
Parkinsonian Disorders
|
0.700 |
GeneticVariation
|
group |
BEFREE |
Missense mutation in both alleles of the TH gene is known to cause dopamine-related phenotypes, including dystonia and infantile Parkinsonism.
|
20809526 |
2010 |
|
Parkinsonian Disorders
|
0.700 |
Biomarker
|
group |
RGD |
Decreased RGS9 protein level in the striatum of rodents undergoing MPTP or 6-OHDA neurotoxicity.
|
20561938 |
2010 |
|
Parkinsonian Disorders
|
0.700 |
GeneticVariation
|
group |
BEFREE |
Levodopa-responsive infantile parkinsonism due to a novel mutation in the tyrosine hydroxylase gene and exacerbation by viral infections.
|
15747353 |
2005 |
|
Parkinsonian Disorders
|
0.700 |
Biomarker
|
group |
BEFREE |
Intravenous nonviral gene therapy causes normalization of striatal tyrosine hydroxylase and reversal of motor impairment in experimental parkinsonism.
|
12573054 |
2003 |
|
Parkinsonian Disorders
|
0.700 |
GeneticVariation
|
group |
BEFREE |
Four novel mutations in the tyrosine hydroxylase gene in patients with infantile parkinsonism.
|
11246459 |
2000 |
|
Parkinsonian Disorders
|
0.700 |
Biomarker
|
group |
CTD_human |
Four novel mutations in the tyrosine hydroxylase gene in patients with infantile parkinsonism.
|
11246459 |
2000 |
|
Parkinsonian Disorders
|
0.700 |
GeneticVariation
|
group |
BEFREE |
The phenotype of AR-DRD with the Leu205Pro mutation in the TH gene, which produces a severe decrease in TH activity to 1.5% of that of the wild type, was severe, not dystonia/Segawa's syndrome, but early-onset parkinsonism.
|
10661862 |
1999 |
|
Parkinsonian Disorders
|
0.700 |
GeneticVariation
|
group |
BEFREE |
Functional polymorphisms of the TH gene may be involved in the pathogenesis of neuropsychiatric diseases such as schizophrenia, affective disorders, and Parkinsonism.
|
9613851 |
1998 |
|
Parkinsonian Disorders
|
0.700 |
AlteredExpression
|
group |
BEFREE |
Our results indicate that the differential regulation of mRNAs encoding TH and DAT is similar in the parkinsonian disorders (PD and AD/Park) even though the degree of cell death is very different.
|
9399211 |
1997 |
|
Parkinsonian Disorders
|
0.700 |
GeneticVariation
|
group |
BEFREE |
GTP cyclohydrolase I gene, tetrahydrobiopterin, and tyrosine hydroxylase gene: their relations to dystonia and parkinsonism.
|
9182249 |
1996 |
|
Parkinsonian Disorders
|
0.700 |
Biomarker
|
group |
CTD_human |
Recessively inherited L-DOPA-responsive parkinsonism in infancy caused by a point mutation (L205P) in the tyrosine hydroxylase gene.
|
8817341 |
1996 |
|
Parkinsonian Disorders
|
0.700 |
GeneticVariation
|
group |
BEFREE |
Recessively inherited L-DOPA-responsive parkinsonism in infancy caused by a point mutation (L205P) in the tyrosine hydroxylase gene.
|
8817341 |
1996 |
|
Parkinsonian Disorders
|
0.700 |
Biomarker
|
group |
BEFREE |
Preliminary investigations have examined possible allelic associations, e.g., with alleles of MAO-A and debrisoquine hydroxylase and linkage to the tyrosine hydroxylase gene on chromosome 11p15.5 has been excluded in one study of juvenile familial parkinsonism.
|
1341965 |
1992 |
|
Parkinsonian Disorders
|
0.700 |
Biomarker
|
group |
HPO |
|
|
|